세계의 노인 황반 변성 시장 : 유형별, 치료법별, 전달 방법별, 의료 환경별, 유통 채널별 예측(2025-2030년)

The Age-related Macular Degeneration Market was valued at USD 10.45 billion in 2023, expected to reach USD 11.10 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 16.43 billion by 2030.

Age-related Macular Degeneration (AMD) represents a significant public health concern, being a leading cause of vision loss among the elderly population globally. The market scope encompasses pharmacological therapies, such as anti-vascular endothelial growth factor (anti-VEGF) treatments, along with emerging gene therapies and stem cell approaches. The necessity for advancing AMD therapeutics is underscored by an aging global population and increasing disease prevalence, driving demand for more effective and accessible treatments. Applications extend primarily to the ophthalmology sector, targeting both wet and dry forms of AMD, with end-use spanning hospitals, specialized eye clinics, and research institutions. Key factors influencing growth include rising healthcare expenditure, advancements in biomedical technology, and increasing awareness of early AMD detection and management. Notably, the growing geriatric population in developing economies presents substantial opportunity. Companies can leverage these opportunities by investing in R&D to innovate treatments with better efficacy and safety profiles. Collaborative partnerships with healthcare providers and patient advocacy groups are recommended to enhance market outreach.

Nonetheless, market expansion faces limitations due to high treatment costs, regulatory challenges, and potential side effects associated with current AMD therapies. Moreover, the complexity of AMD's etiology complicates the development of one-size-fits-all solutions, emphasizing the need for personalized medicine. Innovation could focus on genetic research to uncover new biomarkers for earlier diagnosis or more tailored therapeutic regimens. Additionally, investment in drug delivery systems that enhance treatment adherence and patient outcomes could be promising. The market is competitive and involves major pharmaceutical companies, biotech firms, and academic research institutions, creating a dynamic landscape that requires strategic agility. Companies should diversify their portfolio to include alternative therapies like nutraceuticals known to support macular health as complementary approaches. Keeping pace with technological advancements in AI for diagnostic support and telemedicine also holds potential for new market endeavors.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing number of geriatric population across the world
  • Surging use of laser therapy and anti-angiogenesis drugs
  • Increasing diagnostics facilities and technology for effective detection of AMD
• Market Restraints
  • Potential risk of drug recalls associated with AMD
• Market Opportunities
  • Significant government policies & funding for AMD
  • Introduction of novel and advanced treatments based on cell therapy and tissue engineering
• Market Challenges
  • Stringent regulatory environment and complex approval of new treatments

Porter's Five Forces: A Strategic Tool for Navigating the Age-related Macular Degeneration Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Age-related Macular Degeneration Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Age-related Macular Degeneration Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Age-related Macular Degeneration Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Age-related Macular Degeneration Market

A detailed market share analysis in the Age-related Macular Degeneration Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Age-related Macular Degeneration Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Age-related Macular Degeneration Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Age-related Macular Degeneration Market

A strategic analysis of the Age-related Macular Degeneration Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., AsclepiX Therapeutics, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biocon Ltd, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Lupin Limited, Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Age-related Macular Degeneration Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration.
• Based on Treatment Modality, market is studied across Pharmaceuticals and Surgical Interventions. The Pharmaceuticals is further studied across Anti-inflammatory Drugs, Anti-VEGF Agents, Antioxidants & Supplements, and Gene Therapy Drugs. The Surgical Interventions is further studied across Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and Vitrectomy.
• Based on Delivery Method, market is studied across Injectable, Intravitreal implants, and Oral.
• Based on Healthcare Setting, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmology Clinics.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing number of geriatric population across the world
    • 5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
    • 5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD
  • 5.1.2. Restraints
    • 5.1.2.1. Potential risk of drug recalls associated with AMD
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant government policies & funding for AMD
    • 5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory environment and complex approval of new treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments
  • 5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration
  • 5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration
  • 5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments
  • 5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country

6. Age-related Macular Degeneration Market, by Type

• 6.1. Introduction
• 6.2. Dry Age-Related Macular Degeneration
• 6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Modality

• 7.1. Introduction
• 7.2. Pharmaceuticals
  • 7.2.1. Anti-inflammatory Drugs
  • 7.2.2. Anti-VEGF Agents
  • 7.2.3. Antioxidants & Supplements
  • 7.2.4. Gene Therapy Drugs
• 7.3. Surgical Interventions
  • 7.3.1. Laser Therapy
  • 7.3.2. Macular Translocation Surgery
  • 7.3.3. Photodynamic Therapy
  • 7.3.4. Vitrectomy

8. Age-related Macular Degeneration Market, by Delivery Method

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Intravitreal implants
• 8.4. Oral

9. Age-related Macular Degeneration Market, by Healthcare Setting

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Ophthalmology Clinics

10. Age-related Macular Degeneration Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Age-related Macular Degeneration Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Age-related Macular Degeneration Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Age-related Macular Degeneration Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision
  • 14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes
  • 14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina
  • 14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients
  • 14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment
  • 14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment
  • 14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results
  • 14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics' AVD-104 targeting age-related macular degeneration
  • 14.3.9. Retinal Degeneration Fund's major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. F. Hoffmann-La Roche Ltd.
  • 14.4.2. Novartis AG
  • 14.4.3. Bayer AG
  • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adverum Biotechnologies, Inc.
• 3. Alkeus Pharmaceuticals, Inc.
• 4. Allegro Ophthalmics, LLC
• 5. Amgen Inc.
• 6. Annexon, Inc.
• 7. Apellis Pharmaceuticals, Inc.
• 8. AsclepiX Therapeutics
• 9. Astellas Pharma Inc.
• 10. Bausch Health Companies Inc.
• 11. Bayer AG
• 12. Biocon Ltd
• 13. Biogen Inc.
• 14. Clearside Biomedical, Inc.
• 15. EyePoint Pharmaceuticals, Inc.
• 16. F. Hoffmann-La Roche Ltd.
• 17. Formycon AG
• 18. Grifols, S.A.
• 19. Ionis Pharmaceuticals, Inc.
• 20. Johnson & Johnson Services, Inc.
• 21. Kodiak Sciences Inc.
• 22. Lineage Cell Therapeutics, Inc.
• 23. Lupin Limited
• 24. Merck & Co., Inc.
• 25. Nicox S.A.
• 26. Novartis AG
• 27. PanOptica, Inc.
• 28. Pfizer Inc.
• 29. Regeneron Pharmaceuticals, Inc.
• 30. Sandoz Group AG
• 31. Sun Pharmaceutical Industries, Ltd.
• 32. Teva Pharmaceutical Industries Ltd.
• 33. Viatris Inc.